256 related articles for article (PubMed ID: 35328587)
1. Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models.
Arellano-García L; Portillo MP; Martínez JA; Milton-Laskibar I
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328587
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
3. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
4. Combination of Probiotics and
Wang W; Xu AL; Li ZC; Li Y; Xu SF; Sang HC; Zhi F
Diabetes Metab J; 2020 Apr; 44(2):336-348. PubMed ID: 31950772
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community.
Geng W; Zhang Y; Yang J; Zhang J; Zhao J; Wang J; Jia L; Wang Y
J Sci Food Agric; 2022 Aug; 102(11):4620-4628. PubMed ID: 35174500
[TBL] [Abstract][Full Text] [Related]
6. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
7. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention.
Kobyliak N; Falalyeyeva T; Virchenko O; Mykhalchyshyn G; Bodnar P; Spivak M; Yankovsky D; Beregova T; Ostapchenko L
BMC Gastroenterol; 2016 Mar; 16():34. PubMed ID: 26976285
[TBL] [Abstract][Full Text] [Related]
8. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption.
Jang HR; Park HJ; Kang D; Chung H; Nam MH; Lee Y; Park JH; Lee HY
Exp Mol Med; 2019 Aug; 51(8):1-14. PubMed ID: 31409765
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of Bacillus probiotics against high-fat diet-induced metabolic disorders in mice.
Kim B; Kwon J; Kim MS; Park H; Ji Y; Holzapfel W; Hyun CK
PLoS One; 2018; 13(12):e0210120. PubMed ID: 30596786
[TBL] [Abstract][Full Text] [Related]
10. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
11. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
12. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
13. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
16. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
17. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
Bakhshimoghaddam F; Alizadeh M
Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
[TBL] [Abstract][Full Text] [Related]
18. Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats.
Liang Y; Liang S; Zhang Y; Deng Y; He Y; Chen Y; Liu C; Lin C; Yang Q
Probiotics Antimicrob Proteins; 2019 Mar; 11(1):175-185. PubMed ID: 29353414
[TBL] [Abstract][Full Text] [Related]
19. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
Duarte SMB; Stefano JT; Oliveira CP
Ann Hepatol; 2019; 18(3):416-421. PubMed ID: 31036494
[TBL] [Abstract][Full Text] [Related]
20. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
